← Back to Search

Device

Vagus Nerve Stimulation for Rheumatoid Arthritis (RESET-RA Trial)

Phase 3
Waitlist Available
Led By Jeffrey R Curtis, MD MPH
Research Sponsored by SetPoint Medical Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
22-75 years of age at screening
Active moderate or severe RA, defined as at least 4/28 tender and 4/28 swollen joints
Must not have
Significant immunodeficiency due to underlying illness
History of stroke or transient ischemic attack, or diagnosis of cerebrovascular fibromuscular dysplasia
Timeline
Screening 28 days
Treatment 24 months
Follow Up 2 months
Awards & highlights
Pivotal Trial

Summary

This trial will assess the safety and efficacy of a new device designed to treat rheumatoid arthritis by stimulating the vagus nerve. The study will enroll 250 subjects at 40 sites, who will either receive active or non-active stimulation. There will be a one-way crossover of control subjects to active stimulation after 12 weeks, and all subjects will receive active stimulation for the next 180 weeks to evaluate long-term safety.

Who is the study for?
Adults aged 22-75 with active, moderate to severe rheumatoid arthritis who haven't responded well or can't tolerate certain advanced RA medications. Participants must be on a stable dose of conventional synthetic DMARD for at least 12 weeks before the trial and continue it through Week 12. People with recurrent fainting episodes, significant psychiatric or substance abuse history, stroke/TIA, serious heart disease, neurological disorders like MS/Alzheimer's/Parkinson's, uncontrolled fibromyalgia, past carotid surgery/splenectomy/vagotomy or tobacco users are excluded.
What is being tested?
The RESET-RA study is testing the SetPoint System device that stimulates the vagus nerve to treat rheumatoid arthritis. The device is implanted via surgery under general anesthesia. Of the enrolled participants, half will receive actual stimulation while the other half will get non-active stimulation as a control group initially; after Week 12 all subjects will receive active stimulation for long-term safety assessment.
What are the potential side effects?
Potential side effects may include complications from neck surgery such as infection or pain at implant site; adverse reactions to anesthesia; possible changes in voice tone due to vagus nerve proximity; discomfort from electrical stimulation; and typical risks associated with any surgical procedure.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 22 and 75 years old.
Select...
I have active rheumatoid arthritis with at least 4 tender and 4 swollen joints.
Select...
I am between 22 and 75 years old.
Select...
I have active rheumatoid arthritis with at least 4 tender and 4 swollen joints.
Select...
I have rheumatoid arthritis and treatments like biologics or JAK inhibitors haven’t worked for me.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a condition that significantly weakens my immune system.
Select...
I have had a stroke, TIA, or have cerebrovascular fibromuscular dysplasia.
Select...
I have a serious heart condition.
Select...
I have a neurological condition like MS, Alzheimer's, or Parkinson's.
Select...
My fibromyalgia is not under control.
Select...
I have had surgery on my carotid artery.
Select...
I have had surgery on my stomach nerves or spleen.
Select...
I frequently faint due to sudden drops in my heart rate and blood pressure.

Timeline

Screening ~ 28 days
Treatment ~ 24 months
Follow Up ~2 months
This trial's timeline: 28 days for screening, 24 months for treatment, and 2 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
the American College of Rheumatology (ACR) 20 response
Secondary study objectives
ACR20 response at Week 12 from Day 0
DAS28-CRP response (MCID -1.2) at Week 12
Diabetes Insipidus
+1 more

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: TreatmentExperimental Treatment3 Interventions
Active stimulation for 1 min once per day
Group II: ControlPlacebo Group3 Interventions
Non-active stimulation for 1 min once per day
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Active stimulation
2022
Completed Phase 3
~340

Find a Location

Logistics

Other reimbursement is provided

Other forms of reimbursement are provided for this trial.

Who is running the clinical trial?

SetPoint Medical CorporationLead Sponsor
6 Previous Clinical Trials
94 Total Patients Enrolled
4 Trials studying Rheumatoid Arthritis
64 Patients Enrolled for Rheumatoid Arthritis
Jeffrey R Curtis, MD MPHPrincipal InvestigatorUniversity of Alabama, Birmingham, AL
John Tesser, MDPrincipal InvestigatorArizona Arthritis and Rheumatology Research, P.C.
Mark Richardson, MD PhDPrincipal InvestigatorMassachusetts General Hospital

Media Library

SetPoint System (Device) Clinical Trial Eligibility Overview. Trial Name: NCT04539964 — Phase 3
Rheumatoid Arthritis Research Study Groups: Treatment, Control
Rheumatoid Arthritis Clinical Trial 2023: SetPoint System Highlights & Side Effects. Trial Name: NCT04539964 — Phase 3
SetPoint System (Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04539964 — Phase 3
Rheumatoid Arthritis Patient Testimony for trial: Trial Name: NCT04539964 — Phase 3
~49 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top